Shifting the Perspective of Therapy Options in Early-Stage NSCLC

Liza Villaruz, MD, discusses the paradigm shift that has occurred in the testing and treatment of patients with early-stage non–small cell lung cancer (NSCLC). Dr Villaruz no longer looks at early-stage NSCLC as a single-disease entity but as a complex disease stage with subsets.

With this perspective shift over the last couple of decades, Dr Villaruz has witnessed the use of genomic testing to guide therapy options that target individual subtypes in early-stage NSCLC.

Medscape © 2023 WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Shifting the Perspective of Therapy Options in Early-Stage NSCLC - Medscape - Jan 30, 2023.